Improved cancer-specific free survival and overall free survival in contemporary metastatic prostate cancer patients: a population-based study-Reference-Cited by-同舟云学术

Improved cancer-specific free survival and overall free survival in contemporary metastatic prostate cancer patients: a population-based study

Published:2017-11-11 Issue:1 Volume:50 Page:71-78
ISSN:0301-1623
Container-title:International Urology and Nephrology
language:en
Short-container-title:Int Urol Nephrol

Author:

Bandini Marco^ORCID,Pompe Raisa S.,Marchioni Michele,Zaffuto Emanuele,Gandaglia Giorgio,Fossati Nicola,Cindolo Luca,Montorsi Francesco,Briganti Alberto,Saad Fred,Karakiewicz Pierre I.

Publisher

Springer Science and Business Media LLC

Subject

Urology,Nephrology

Link

http://link.springer.com/article/10.1007/s11255-017-1744-2/fulltext.html

Reference19 articles.

1. Tangen CM, Hussain MHA, Higano CS et al (2012) Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346). J Urol 188:1164–1169. https://doi.org/10.1016/j.juro.2012.06.046

2. Wu JN, Fish KM, Evans CP et al (2014) No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period. Cancer 120:818–823. https://doi.org/10.1002/cncr.28485

3. Teoh JYC, Ng C-F (2016) Cardiovascular risk after androgen deprivation therapy for prostate cancer: an Asian perspective. Int Urol Nephrol 48:1429–1435. https://doi.org/10.1007/s11255-016-1337-5

4. Cornford P, Bellmunt J, Bolla M et al (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol 71:630–642. https://doi.org/10.1016/j.eururo.2016.08.002

5. Miyake H, Sakai I, Harada K et al (2012) Significance of docetaxel-based chemotherapy as treatment for metastatic castration-resistant prostate cancer in Japanese men over 75 years old. Int Urol Nephrol 44:1697–1703. https://doi.org/10.1007/s11255-012-0223-z

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cellular senescence: A potential mode of circular RNAs regulating prostate cancer;MedComm – Oncology;2023-12

2. LncRNA BRCAT54 is downregulated and inhibits cancer cell proliferation by downregulating miR‐130b‐3p through methylation in prostate cancer;Journal of Biochemical and Molecular Toxicology;2023-10-27

3. Assessing the Efficacy of a 28-Day Comprehensive Online Prostate Cancer Patient Empowerment Program (PC-PEP) in Facilitating Engagement of Prostate Cancer Patients in Their Survivorship Care: A Qualitative Study;Current Oncology;2023-09-21

4. Factors influencing survival in metastatic castration-resistant prostate cancer therapy;Expert Review of Anticancer Therapy;2022-08-30

5. Cost-Effectiveness of Treatment Strategies for Spinal Metastases;Practical Radiation Oncology;2022-05